Brief: Biocept's Target Selector Liquid Biopsy Shows High Accuracy In Monitoring Metastatic Breast Cancer
10/12/2020 13:40
Dec 10 (Reuters) - Biocept Inc BIOC.O :
* BIOCEPT INC - CO'S TARGET SELECTOR LIQUID BIOPSY
DEMONSTRATED
HIGH ACCURACY WHEN USED FOR MONITORING PROGRESSION OF METASTATIC
BREAST CANCER
Source text for Eikon: ID:nPnbwd79a
Further company coverage: BIOC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biocept
See all newsBrief: Biocept Says Trading Of Common Stock Will Be Suspended By Nasdaq At Opening Of Business On Oct 25
U.S. STOCKS ON THE MOVE-Overstock.com, Biocept, Birkenstock
Biocept slumps after filing for bankruptcy protection
Brief: Biocept CEO Antonino Morales Resigns
U.S. STOCKS ON THE MOVE-Albemarle, Novavax, WeWork